Biopharmaceutical company Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with ViiV Healthcare to further the development of ultra-long-acting …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that Janssen Biotech, Inc.
William Blair analyst John Sonnier maintained an Outperform rating on Halozyme Therapeutics (NASDAQ:HALO), following the company’s third-quarter results. No price target was provided.
